sur TRANSGENE (EPA:TNG)
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Strasbourg, France, September 10, 2024 – Transgene, a biotech company focused on virus-based immunotherapies for cancer treatment, has appointed Dr. Emmanuelle Dochy as Chief Medical Officer (CMO) and Dr. Maurizio Ceppi as Chief Scientific Officer (CSO). Both are experts in advancing cancer immunotherapies and precision medicine.
Dr. Dochy, with over 15 years in the pharmaceutical industry, previously worked at Bayer and Sanofi, where she held senior roles. She will oversee Transgene’s clinical development, including the TG4050 cancer vaccine.
Dr. Ceppi also brings 15 years of experience in oncology. He has worked with Roche and iTeos Therapeutics, specializing in cancer immunotherapy and precision medicine. At Transgene, he will lead scientific innovation, focusing on novel immunotherapies.
These appointments come as Transgene advances its innovative therapeutic programs, aiming to deliver new cancer treatments to patients.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TRANSGENE